Literature DB >> 20959960

Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis.

C B Confavreux1, R D Chapurlat.   

Abstract

Inflammatory joint diseases are responsible of chronic systemic inflammation, joint degradations, deformities, and altered quality of life. Patients suffering from chronic rheumatic diseases also present increased bone fragility and increased fracture risk. Registration of biologic therapies has deeply modified care in rheumatic diseases, especially in rheumatoid arthritis and ankylosing spondylitis. The available biologics are the anti proinflammatory cytokine therapies (TNFα blockers, anakinra and tocilizumab) and the biologics active on T cell activation (abatacept and rituximab). These drugs succeeded in blocking disease activity and joint degradation. They are also able to stop systemic bone loss among patients with inflammatory rheumatic diseases. In this review, we present the current understanding of the inflammatory-induced bone loss and the skeletal effects of biologic therapies in inflammatory joint diseases.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20959960     DOI： 10.1007/s00198-010-1462-4

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


  127 in total

1.  Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products.

Authors:  P Garnero; P Jouvenne; N Buchs; P D Delmas; P Miossec
Journal:  Bone       Date:  1999-04       Impact factor: 4.398

2.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

3.  Osteoclasts are essential for TNF-alpha-mediated joint destruction.

Authors:  Kurt Redlich; Silvia Hayer; Romeo Ricci; Jean-Pierre David; Makiyeh Tohidast-Akrad; George Kollias; Günter Steiner; Josef S Smolen; Erwin F Wagner; Georg Schett
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

4.  Osteoporosis screening in systemic lupus erythematosus: impact of disease duration and organ damage.

Authors:  A Becker; R Fischer; W A Scherbaum; M Schneider
Journal:  Lupus       Date:  2001       Impact factor: 2.911

5.  Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study.

Authors:  J F Maillefert; L S Aho; A El Maghraoui; M Dougados; C Roux
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

6.  Bone mineral mass is associated with interleukin 1 receptor autoantigen and TNF-alpha gene polymorphisms in post-menopausal Mediterranean women.

Authors:  R Fontova; C Gutiérrez; J Vendrell; M Broch; I Vendrell; I Simón; J M Fernández-Real; C Richart
Journal:  J Endocrinol Invest       Date:  2002-09       Impact factor: 4.256

7.  CTLA-4 directly inhibits osteoclast formation.

Authors:  R Axmann; S Herman; M Zaiss; S Franz; K Polzer; J Zwerina; M Herrmann; J Smolen; G Schett
Journal:  Ann Rheum Dis       Date:  2008-01-18       Impact factor: 19.103

Review 8.  The role of interleukin-1 in bone resorption in rheumatoid arthritis.

Authors:  V Strand; A F Kavanaugh
Journal:  Rheumatology (Oxford)       Date:  2004-06       Impact factor: 7.580

9.  Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers.

Authors:  Steven Young-Min; Tim Cawston; Nicola Marshall; David Coady; Stephan Christgau; Tore Saxne; Simon Robins; Ian Griffiths
Journal:  Arthritis Rheum       Date:  2007-10

10.  Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis.

Authors:  Philip G Conaghan; Philip O'Connor; Dennis McGonagle; Paul Astin; Richard J Wakefield; Wayne W Gibbon; Mark Quinn; Zunaid Karim; Michael J Green; Susanna Proudman; John Isaacs; Paul Emery
Journal:  Arthritis Rheum       Date:  2003-01
View more
  16 in total

1.  Factors influencing spinal sagittal balance, bone mineral density, and Oswestry Disability Index outcome measures in patients with rheumatoid arthritis.

Authors:  Kazutaka Masamoto; Bungo Otsuki; Shunsuke Fujibayashi; Koichiro Shima; Hiromu Ito; Moritoshi Furu; Motomu Hashimoto; Masao Tanaka; Stephen Lyman; Hiroyuki Yoshitomi; Shimei Tanida; Tsuneyo Mimori; Shuichi Matsuda
Journal:  Eur Spine J       Date:  2017-11-28       Impact factor: 3.134

2.  [Local and systemic bone effects of rheumatoid arthritis].

Authors:  M Rauner; L C Hofbauer; M Aringer
Journal:  Z Rheumatol       Date:  2012-12       Impact factor: 1.372

Review 3.  Update on Imaging-Based Measurement of Bone Mineral Density and Quality.

Authors:  Thomas M Link; Galateia Kazakia
Journal:  Curr Rheumatol Rep       Date:  2020-04-09       Impact factor: 4.592

4.  Vertebral fractures are increased in rheumatoid arthritis despite recent therapeutic advances: a case-control study.

Authors:  N Guañabens; J M Olmos; J L Hernández; D Cerdà; C Hidalgo Calleja; J A Martinez López; L Arboleya; F J Aguilar Del Rey; S Martinez Pardo; I Ros Vilamajó; X Suris Armangué; D Grados; C Beltrán Audera; E Suero-Rosario; I Gómez Gracia; A Salmoral Chamizo; I Martín-Esteve; H Florez; A Naranjo; S Castañeda; S Ojeda Bruno; S García Carazo; A García Vadillo; L López Vives; À Martínez-Ferrer; H Borrell Paños; P Aguado Acín; R Castellanos-Moreira; C Tebé; C Gómez-Vaquero
Journal:  Osteoporos Int       Date:  2021-01-18       Impact factor: 4.507

5.  Inflammatory synovial fluid microenvironment drives primary human chondrocytes to actively take part in inflammatory joint diseases.

Authors:  Eric Röhner; Georg Matziolis; Carsten Perka; Bernd Füchtmeier; Timo Gaber; Gerd-Rüdiger Burmester; Frank Buttgereit; Paula Hoff
Journal:  Immunol Res       Date:  2012-06       Impact factor: 2.829

6.  [Multimorbidity in elderly rheumatic patients part 1].

Authors:  H-J Lakomek; T Brabant; M Lakomek; D Lüttje
Journal:  Z Rheumatol       Date:  2013-08       Impact factor: 1.372

Review 7.  Interpretation and use of FRAX in clinical practice.

Authors:  J A Kanis; D Hans; C Cooper; S Baim; J P Bilezikian; N Binkley; J A Cauley; J E Compston; B Dawson-Hughes; G El-Hajj Fuleihan; H Johansson; W D Leslie; E M Lewiecki; M Luckey; A Oden; S E Papapoulos; C Poiana; R Rizzoli; D A Wahl; E V McCloskey
Journal:  Osteoporos Int       Date:  2011-07-21       Impact factor: 4.507

Review 8.  Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases.

Authors:  Harjit P Bhattoa; Zoltán Szekanecz; Boglárka Soós; Ágnes Szentpétery; Hennie G Raterman; Willem F Lems
Journal:  Nat Rev Rheumatol       Date:  2022-03-10       Impact factor: 20.543

9.  Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics.

Authors:  Kengo Takahashi; Takao Setoguchi; Hiroki Tawaratsumida; Yoshiya Arishima; Hiroyuki Tominaga; Yasuhiro Ishidou; Satoshi Nagano; Sanae Shigemizu; Noriko Aoki; Masaki Akimoto; Hideo Otsubo; Takemasa Matsuda; Hironori Kakoi; Toshihiko Izumi; Shunsuke Nakamura; Masahiro Yokouchi; Nobuhiko Sunahara; Setsuro Komiya
Journal:  BMC Musculoskelet Disord       Date:  2015-09-30       Impact factor: 2.362

10.  Effect of sclerostin-neutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: a microCT study.

Authors:  Massimo Marenzana; Alex Vugler; Adrian Moore; Martyn Robinson
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.